Health Care and Biotech

Another big sell off in Greek bonds had traders exiting the Aussie last night as the SPI Overnight headed south despite a flat close on Wall Street.

Many in the market are expecting CSL to deliver solid earnings growth in coming years but Morgan Stanley suggests earnings risk is actually to the downside.

Citi has initiated coverage on QRxPharma, seeing significant upside potential as the company develops its products designed for the moderate-to-severe pain relief market.

In the ongoing process of post-GFC regulatory changes, ASIC is looking to formalise stock broker recommendations in the wake of investor complaints.

The passage of the healthcare bill sparked a rally on Wall Street not all were expecting. Dow up 43. (Locked for subscribers until 10:00 AEDST)

Faced with tougher competition in the Australian diagnostic imaging market and reduced government spending the growth potential of Sonic Health’s German operations assumes greater importance.

Southern Cross Equities believes tissue repair technology play bioMD offers upside as its clinical trials are progressing.

ResMed beat market expectations with its second quarter result.

The US has reduced its swine flu dose contract with CSL but brokers estimate the earnings impact of the change will be minimal.

A surge in M&A activity and broker upgrades sent Wall Street higher last night despite a stronger greenback. Dow up 85.